Natera Expands Intellectual Property Portfolio With New Patents in Tumor-Informed MRDBusiness Wire • 03/04/25
Natera Announces Medicare Coverage of Signatera™ for Surveillance in Lung CancerBusiness Wire • 02/25/25
Natera to Report its Fourth Quarter and Full Year Results on February 27, 2025Business Wire • 02/18/25
NCCN Strengthens Guidance on ctDNA in Colon Cancer, Rectal Cancer, and Merkel Cell CarcinomaBusiness Wire • 02/10/25
Billionaire Stanley Druckenmiller says the AI boom could get much bigger – These are the stocks he owns24/7 Wall Street • 02/04/25
Natera Announces Successful Readout of Randomized, Phase III CALGB (Alliance) / SWOG 80702 Clinical Trial in Colorectal CancerBusiness Wire • 01/25/25
Natera CEO Steve Chapman Recognized as a 2024 Top Healthcare Technology CEO and BioTechnology Innovator of the YearBusiness Wire • 01/17/25
Natera Announces Innovation Roadmap, with Advancements in MRD and Early Cancer DetectionBusiness Wire • 01/15/25
Court Grants Natera's Request to Include Additional Patent in its Lawsuit Against NeoGenomicsBusiness Wire • 12/17/24
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon CancerBusiness Wire • 12/12/24
Clinical Validation Study on Natera's Fetal RhD NIPT Published in Obstetrics & GynecologyBusiness Wire • 12/02/24